Rechercher un médicament orphelin
Autre(s) option(s) de recherche
Autorisation de mise sur le marché avec désignation orpheline - Etats-Unis
- Nom commercial: HUMIRA
- Code ATC : L04AB04
- Identifiant UE: -
- Date d'AMM : 23/09/2014
- Détenteur de l'AMM: ABBVIE INC.
Juvenile Idiopathic Arthritis
HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate.
Pediatric Crohn's Disease
HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.